Strongbridge Biopharma plc.
SBBP
SBBP was delisted on the 5th of October, 2021.
49 hedge funds and large institutions have $149M invested in Strongbridge Biopharma plc. in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 18 reducing their positions, and 23 closing their positions.
255% more call options, than puts
Call options by funds: $39K | Put options by funds: $11K
6% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 18
21% less capital invested
Capital invested by funds: $187M → $149M (-$38.7M)
23% less funds holding
Funds holding: 64 → 49 (-15)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
65% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$4.59M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.58M |
| 3 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$2.53M |
| 4 |
AC
Armistice Capital
New York
|
+$2.52M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
+$2.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSC
Lyon Street Capital
Sausalito,
California
|
-$8.73M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$5.12M |
| 3 |
PM
Precept Management
Dallas,
Texas
|
-$2.07M |
| 4 |
PA
Perceptive Advisors
New York
|
-$1.65M |
| 5 |
Goldman Sachs
New York
|
-$1.36M |
SBBP Hedge Fund Activity: Q3 2018 in Review
49 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q3 2018, worth a combined $149M — down 21% from $187M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of SBBP and 8 opened new positions — a net loss of 15 holders — while 18 trimmed existing stakes and 17 added.
The largest buyer was Caxton Corporation, adding an estimated $4.59M. The largest seller was Lyon Street Capital, cutting an estimated $8.73M.
- 49 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q3 2018, down from 64 in Q2 2018.
- Funds reported $149M of Strongbridge Biopharma plc. stock for Q3 2018, down 21% quarter-over-quarter.
- 8 funds opened new Strongbridge Biopharma plc. positions in Q3 2018 and 23 closed out, a net change of -15 holders.
- The largest Strongbridge Biopharma plc. buyer in Q3 2018 was Caxton Corporation, an estimated $4.59M added.
- The largest Strongbridge Biopharma plc. seller in Q3 2018 was Lyon Street Capital, an estimated $8.73M sold.
Based on aggregated 13F filings for Q3 2018.